Mubadala Exits Evotec SE, Selling Entire Stake in Block Trade
EVO is trading near its 52-week low of $1.33 (7.1% above the low).
Summary
Mubadala Investment Company sold its entire stake in Evotec SE, divesting 11.48 million ordinary shares in a block trade on October 9, 2026, ending its position as a major shareholder.
Key Events · Ownership and Investor Activity · EVO
-
Mubadala Exits Entire Stake
Mubadala Investment Company sold all 11,481,502 ordinary shares of Evotec SE on October 9, 2026, in a privately negotiated block trade, completely divesting its investment.
-
Block Trade Pricing
The sale was executed at EUR 2.5109 per ordinary share, with an additional 1 ADS sold at $1.56, representing a full exit from a position accumulated since 2020.
-
Ownership Falls Below 5%
Following the sale, Mubadala and its related entities ceased to be beneficial owners of more than 5% of Evotec's ordinary shares, ending their status as a major shareholder.
-
Context of Recent Financial Struggles
The divestment follows Evotec's H1 2026 net loss of €168.6M driven by restructuring costs, and comes just days after the company reported preliminary 9M revenue of ~€465M that beat expectations.
Analysis · EVO · Life Sciences
Mubadala Investment Company, a sovereign wealth fund, has completely divested its stake in Evotec SE, selling 11,481,502 ordinary shares at EUR 2.5109 per share in a privately negotiated block trade on October 9, 2026. This represents a full exit from a position built since 2020, removing a major institutional shareholder. The sale comes amid a challenging period for Evotec, which reported a significant H1 net loss and restructuring costs, and just days after the company announced preliminary 9M results that beat expectations. The block trade price of EUR 2.5109 per share is notably higher than the current stock price of $1.425, suggesting the buyer paid a premium for the block, though the exact premium cannot be determined without the reference price at the time of the transaction.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 39.1% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVO was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.2M. The 52-week trading range was $1.33 to $4.27. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.